Su­ven Life Sci­ences re­ceives patents for new chem­i­cal en­ti­ties

BioSpectrum (India) - - COMPANY NEWS -

Su­ven Life Sci­ences has se­cured the process patents from Europe, Ja­pan and New Zealand. The com­pany has re­ceived patents for new chem­i­cal en­ti­ties (NCEs) which are for the treat­ment of dis­or­ders as­so­ci­ated with neu­rode­gen­er­a­tive dis­eases and these patents are valid through 2034.

Su­ven Life Sci­ences is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on discovering, de­vel­op­ing and com­mer­cial­is­ing novel phar­ma­ceu­ti­cal prod­ucts, which are best in class CNS ther­a­pies us­ing GPCR tar­gets.

These process patents are for com­pany’s pipe­line com­pounds which are in the class of se­lec­tive 5HT6 com­pounds and are be­ing devel­oped as ther­a­peu­tic agents and use­ful in the treat­ment of cog­ni­tive im­pair­ment as­so­ci­ated with neu­rode­gen­er­a­tive dis­or­ders like Alzheimer’s dis­ease, At­ten­tion de­fi­cient hyper­ac­tiv­ity dis­or­der (ADHD), Hunt­ing­ton’s dis­ease, Parkin­son and Schizophre­nia.

The com­pany is very pleased by the grant of these patents to Su­ven for the pipe­line of mol­e­cules in CNS arena that are be­ing devel­oped for cog­ni­tive dis­or­ders with high un­met med­i­cal need with huge mar­ket po­ten­tial glob­ally.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.